How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature

Ozkan Alan,Okan Kuzhan,Sinan Koca,Tugba Akin Telli,Tugba basoglu Tuylu,Ozlem Ercelep,Deniz Filinte,Yildiz Sengul,Huseyin Arikan,Serap Kaya,Nalan Akgul Babacan,Faysal Dane,Perran Fulden Yumuk

How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature

2019

Ozkan Alan
Okan Kuzhan
Sinan Koca
Tugba Akin Telli
Tugba basoglu Tuylu
Ozlem Ercelep
Deniz Filinte
Yildiz Sengul
Huseyin Arikan
Serap Kaya
Nalan Akgul Babacan
Faysal Dane
Perran Fulden Yumuk

IntroductionInflammatory myofibroblastic tumor is a rare disease which is typically seen in children and young adults. Approximately half of the inflammatory myofibroblastic tumors contain transloc...

Keywords:

Myofibroblastic tumors
ALK Translocation
Anesthesia
Crizotinib
Cancer research
Medicine
Young adult
Anaplastic lymphoma kinase
Rare disease
complete response
Ceritinib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations